ArticleTherapeutics and clinical risk management2009
Guidelines for the treatment of bacterial vaginosis: focus on tinidazole.
Article in Therapeutics and clinical risk management, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 26 citations in OpenAlex.
- Randomized, double-blind, comparative study of oral metronidazole and tinidazole in treatment of bacterial vaginosis.Indian journal of pharmacologyTrial
- Fighting polymicrobial biofilms in bacterial vaginosis.Microbial biotechnology · 2023Review
- The Female Vaginal Microbiome in Health and Bacterial Vaginosis.Frontiers in cellular and infection microbiology · 2021Review
- Bacterial Vaginosis: What Do We Currently Know?Frontiers in cellular and infection microbiology · 2021Review
- Electrochemical Behaviour of Tinidazole at 1,4-Benzoquinone Modified Carbon Paste Electrode and Its Direct Determination in Pharmaceutical Tablets and Urine by Differential Pulse Voltammetry.Journal of analytical methods in chemistry · 2017Article
- Article
- Bacterial Vaginosis Biofilms: Challenges to Current Therapies and Emerging Solutions.Frontiers in microbiology · 2015Review
- Bacterial vaginosis, Atopobium vaginae and nifuratel.Current clinical pharmacology · 2012Review
- Bacterial vaginosis: Etiology and modalities of treatment-A brief note.Journal of pharmacy & bioallied sciences · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial vaginosis (BV) is a complex vaginal infection most commonly associated with women of child-bearing age. Risk factors for BV are numerous. There are currently multiple clinical and laboratory tests for diagnosis of BV, including the most commonly used diagnostic methods: Amsel's criteria or Nugent's Gram stain scale. The mainstay of BV therapy is metronidazole, but tinidazole as well as a few other agents have also been used successfully. Tinidazole is the second nitroimidazole antiprotozoal agent and a structural derivative of metronidazole. With a favorable pharmacokinetic profile and reduced side effects, tinidazole is an alternative agent for BV treatment. There are minimal head-to-head comparative data to establish tinidazole's superiority to metronidazole or other therapeutic agents. Available data suggest tinidazole has a role in special populations particularly for refractory or relapsing BV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.